The modulation in GAD67 expression during newborn cell maturation suggests a possible retard in the maturation process.
This hypothesis is, however, weakened by the fact that in experimental models ERN tumour cells display higher radiosensitivity than ERP tumour cells [ 21], thus suggesting a possible retarding effect contrary to the observed one.
Both findings may be complementary, in that it is possible that retarded decomposition causes the formation of copper-fixing organic compounds, and thus, by stimulating the decomposition rate by drainage, the same effect would be obtained as a copper dressing.
The results provide insight into a possible alternative means of retarding wear-type corrugation growth.
A chrondroprotective effect was provided by intra-articular injection of MMP-3 inhibitor, which not only confirmed the important role of MMP-3 in the changes of articular cartilage induced by excessive running load, but also suggested a possible effective treatment for retarding such osteoarthritic changes.
As it is already done for osteoporosis associated with other pathologies (like lymphoblastic leukemia) [22], their assumed use is rational, but new clinical trials are needed to evaluate a possible decrease in bone growth and retarded prosthesis integration.
During the early stages of osteoarthritis it may be possible to retard the destructive process by enhancing the production of aggrecan and inhibiting its degradation.
In the early stages of OA, prior to extensive collagen damage, it may be possible to retard or even reverse the degenerative process by the administration of agents that promote aggrecan synthesis and prevent its degradation.
This is again against the requirement that all equipment and areas within food premises must be kept clean, and carcasses should go into the cooler as soon as possible to retard bacterial growth and extend the shelf-life [ 15, 16].
Our findings suggest intra-articular Hylan G-F 20 may have the potential to retard the progression of knee OA and serve as a possible disease-modifying agent for OA which warrant further evaluation in larger clinical trials.
